MINIMUM bio has developed a versatile, high throughput discovery technology with broad applications in the development of new therapeutic products and the repositioning of existing drugs. The Company’s expertise and know-how is based on our phage display technology platform that permits us to rapidly identify proteins that bind to bioactive molecules of interest. The Company has repurposed antibody phage display for drug target discovery and believes that this platform is a powerful method that can also be used to identify protein targets of small molecules, biologics and other bioactive compounds, and has significant advantages over conventional and mass spectrometry-based approaches. Advantages include: increased speed, less background and less bias toward common, high-abundance, but low affinity targets. Over the past 15 years we have been improving and refining the Phage Display technique (‘mercurious™’) to the point where we can now rapidly isolate the protein binding partner(s) for any small molecule, biologic or natural product.

MINIMUM bio is pursuing a fee-for-service business strategy (CRO) for large and small Pharma which includes: (i) cDNA and gDNA library construction in phage; (ii) biotinylation of lead compounds; (iii) discovery of new therapeutic targets using mercurious.

The Company’s mercurious process generally consists of: (i) generating a Phage Display library; (ii) screening the library and separating phages that display proteins (including protein domains) that bind to the molecule of interest; and (iii) sequencing the DNA inside individual phage or phage populations to identify the binding protein or motif.

We Provide Customized Drug Target Identification Solutions to Pharma for:

• Deconvoluting Phenotypic Screening Results
• Drug Repositioning
• New Target Identification
• Real/Alternative Target Identification
• Off-Target Identification